Dr. Robert Krance, MD
Claim this profileTexas Children's Hospital - Baylor Medical Center
Studies T-Lymphoblastic Leukemia/Lymphoma
Studies Uterine Tumors
3 reported clinical trials
3 drugs studied
Affiliated Hospitals
Clinical Trials Robert Krance, MD is currently running
CD34-Selected Stem Cell Transplant
for Bone Marrow Transplant
Participants are being asked to take part in this study because treatment of his or her disease requires a stem cell transplant. Stem cells or "mother" cells are the source of normal blood cells and lead to recovery of blood counts after bone marrow transplantation. Unfortunately, there is not a perfectly matched stem cell donor (like a sister or brother) for the participant and his or her disease does not permit enough time to identify another donor (like someone from a registry list that is not his or her relative) or another suitable donor has not been identified. However, a close relative of the patient has been identified whose stem cells are not a perfect match, but can be used. Alternatively, the patient may have already received a stem cell transplant but have evidence of mixed chimerism, which means some of the patient's own bone marrow cells are present, rather than all of the donor's cells. This may lead to an increased risk of the disease coming back. Or, the patient may have all donor cells but his or her bone marrow is not working very well, which may lead to frequent blood or platelet (cells that help in clotting blood) transfusions or infection. Regardless of the reason, it may be necessary to isolate stem cells from a haploidentical (half-match) donor in order to provide bone marrow function. Because the stem cells from the donor are only half-matched to the participant, the risk of graft-versus-host disease (GvHD) is very high. GvHD is a complication after transplant caused by donor T cells (graft) that attack the transplant recipient, and this complication can cause death after transplant. Thus, it is important that the donor's blood cells are treated to minimize cells that are most likely to attack the host's tissues. This is done by using a special device to capture the CD34+ stem cells from the donor's stem cell product prior to giving the cells to the host. This method minimizes the donor T cells, which are responsible for causing GvHD. Purpose: In an effort to lower the occurrences and severity of graft-versus-host disease in patients and to lower the rate of transplant failure, investigators would like to specially treat the donor's blood cells to minimize the cells that are most likely to attack the patient's tissues.
Recruiting1 award N/A8 criteria
Unlicensed Cord Blood Transplant
for Blood/Immune System Disorders
This trial is testing the safety of giving patients special blood from umbilical cords. The study focuses on patients who receive these infusions to see if there are any serious side effects. The cord blood has special cells that can help make new blood cells in the body. Umbilical cord blood has been used in the treatment of various diseases for many years, including leukemia, lymphoma, and congenital immunodeficiency.
Recruiting1 award Phase 21 criteria
More about Robert Krance, MD
Clinical Trial Related13 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Robert Krance, MD has experience with
- Unlicensed Cryopreserved Cord Blood Units
- CliniMACS CD34 Reagent System
- Unlicensed CBU
Breakdown of trials Robert Krance, MD has run
T-Lymphoblastic Leukemia/Lymphoma
Uterine Tumors
Acute Lymphoblastic Leukemia
Myeloid Leukemia
Chronic Myelogenous Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Robert Krance, MD specialize in?
Robert Krance, MD focuses on T-Lymphoblastic Leukemia/Lymphoma and Uterine Tumors. In particular, much of their work with T-Lymphoblastic Leukemia/Lymphoma has involved treating patients, or patients who are undergoing treatment.
Is Robert Krance, MD currently recruiting for clinical trials?
Yes, Robert Krance, MD is currently recruiting for 2 clinical trials in Houston Texas. If you're interested in participating, you should apply.
Are there any treatments that Robert Krance, MD has studied deeply?
Yes, Robert Krance, MD has studied treatments such as Unlicensed Cryopreserved Cord Blood Units, CliniMACS CD34 Reagent system, Unlicensed CBU.
What is the best way to schedule an appointment with Robert Krance, MD?
Apply for one of the trials that Robert Krance, MD is conducting.
What is the office address of Robert Krance, MD?
The office of Robert Krance, MD is located at: Texas Children's Hospital - Baylor Medical Center, Houston, Texas 77030 United States. This is the address for their practice at the Texas Children's Hospital - Baylor Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.